Drug Trial Radar · NCT04179734
Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder
Last checked: Nov 19, 2026Latest source record: Aug 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Oct 7, 2019
Primary completion
Oct 6, 2020
Study completion Oct 6, 2020
Sponsor
- Lead sponsor
- Imperial College Healthcare NHS TrustAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- AMAG Pharmaceuticals, Inc.
- First posted
- Nov 27, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomised, double-blind, placebo-controlled, two-way crossover physiological study. Designed to evaluate the effects of melanocortin-4 receptor (MC4R) activation on brain activity patterns and behavioural psychometric measures of sexual arousal during visual erotic stimuli in approximately 40 right-handed, heterosexual, premenopausal women aged 18 years and over with Hypoactive Sexual Desire Disorder (HSDD) for at least a 6 month duration.
Conditions
- Hypoactive Sexual Desire Disorder
Interventions
BremelanotideDrug
Melanocortin-4 receptor agonist subcutaneous injection.
PlaceboDrug
Placebo subcutaenous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in Blood Oxygen Level Dependent (BOLD) Signal Change on Functional MRITime frame: Baseline and 15 minutes
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Imperial College Healthcare NHS Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.